Runs a network of standalone dialysis clinics delivering chronic outpatient kidney care, with the core business being the same procedure replicated across geographies. The company operates both own clinics and clinics under public-private partnership contracts with state governments such as Uttarakhand and Andhra Pradesh. Beyond India, it has entered the Philippines, Uzbekistan and is in the investment phase in Saudi Arabia, where a Ministry of Health dialysis tender is at the expression-of-interest stage. International markets command materially higher per-treatment prices than India, and the company is rolling up unorganised clinic operators in those geographies. On costs, materials (consumables such as dialyzers and blood lines) are the largest line at 22.7% of revenue, with employees at 17.2%; depreciation runs at 9.1% and capex at 11.9% of revenue, consistent with an asset-heavy clinic model. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. India dialysis clinic services, International dialysis clinic services (42%), Public-private partnership contracts. Asset-heavy, fixed-capacity chronic care delivery with multi-country roll-up model
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 999 |
| EBITDA (ex other income) | 227 |
| margin % | 22.7 |
| Owners' profit | 77 |
| EPS, as reported (₹) | 8.48 |
| ROE % · ROCE % | 6.9 · 13.7 |
| Debt / equity (x) | 0.07 |
| Cash from operations | 233 |
| Capex | (119) |
| ₹ crore | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 260 | 266 | 282 |
| Profit before tax | 36 | 36 | 45 |
| Net profit | 32 | 30 | 32 |
| EPS (₹) | 3.43 | 3.03 | 3.19 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. | 31,794 | 45.7 | 12.51 | 37.0 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 15,456 | 82.4 | 16.15 | 43.1 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 12,088 | 25.0 | 7.93 | 28.9 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 8,797 | 32.3 | 15.01 | 32.1 | 27.8 | 33.2 | 10.9 | 33.9 |
| NEPHROCARE HEALTH SERV L ◆ | 7,678 | 79.3 | 6.88 | 30.4 | 6.9 | 8.6 | — | 25.3 |
| KRSNAA DIAGNOSTICS LTD | 1,794 | 18.4 | 1.83 | 9.0 | 10.3 | 8.4 | — | 27.7 |
| SURAKSHA DIAGNOSTIC LTD | 1,693 | 47.2 | 6.95 | 17.2 | 12.9 | 11.5 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 3 Sept 2026 · Nephrocare grants 401,362 employee stock options at Rs 230 each | capital market events | medium | — | — |
| 1 Sept 2026 · NephroPlus subsidiary to acquire 100% stake in Dialysis Center Almaty, Kazakhstan | strategic transactions | medium | — | — |
| 31 Aug 2026 · Tax demand on Uzbekistan subsidiary, about Rs 14.79 crore exposure | regulatory legal | high | — | — |
| 19 Aug 2026 · NephroPlus Q1 FY27: Revenue up 23.7%, EBITDA margin expands 120 bps | investor communications | medium | — | — |
| 17 Aug 2026 · NephroPlus Philippines subsidiary buys dialysis center assets for PhP 75 Million | strategic transactions | high | — | — |
| 13 Aug 2026 · NephroPlus 17th AGM results: all 6 resolutions passed by shareholders | board shareholder meetings | low | — | — |
| 13 Aug 2026 · Nephrocare to attend MOSL investor conference on Aug 18 | investor communications | low | — | — |
| 13 Aug 2026 · Nephrocare unit acquires dialysis center assets in Philippines for PhP 71.8M | strategic transactions | medium | — | — |
| 12 Aug 2026 · Nephrocare shares audio link for Q1FY27 earnings call held on August 12, 2026 | investor communications | medium | — | — |
| 11 Aug 2026 · Monitoring Agency Report on IPO proceeds for Q1 FY27 | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|
| — |
| 36.0 |
| 3B BLACKBIO DX LTD. | 1,217 | 20.3 | 3.67 | 14.3 | 18.1 | 22.5 | (8.9) | 52.6 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 79.3 | 23.2 | 26 of 29 | 11% |
| P/B | 6.9 | 2.3 | 17 of 24 | 30% |
| ROCE | 8.6 | 6.1 | 11 of 29 | 64% |
| ROE | 6.9 | 7.3 | 14 of 26 | 48% |
| Debt / Equity | 0.1 | 0.0 | 16 of 26 | 40% |
| EBITDA margin | 25.3 | 25.6 | 13 of 24 | 48% |
| Market cap | 7678 | 38 | 5 of 30 | 86% |
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
